BD (Becton, Dickinson and Company) today announced the completion
of its acquisition of Carmel Pharma, AB, a Swedish company that manufactures
the PhaSeal® System, a closed-system drug transfer device for the
safe handling of hazardous drugs that are packaged in vials. The acquisition
expands the scope of BD’s healthcare worker safety emphasis to include
hazardous drug exposure reduction.
“Carmel Pharma is a leader in an early-stage market
with significant long-term growth potential,” said Alberto Mas, President,
BD Medical – Medical Surgical Systems. “We’re excited to begin moving
forward to address the critically important issue of hazardous drug exposure to
healthcare providers by raising awareness, driving advocacy efforts, developing
pharmacy and nursing relationships, and expanding market reach around the world
for this product category.”
“We are pleased to welcome this new platform and these
new associates to BD,” said Alexandre Conroy, President, BD – Western Europe. “Healthcare worker safety is an
important focus for BD in Europe, and
globally. Through this acquisition, BD will be able to provide an enhanced
suite of safety products to our customers.”
